TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Percentage of Participants Who Experienced Venous Thromboembolism Event (VTE) or VTE-related Death
Endpoint domain: Mortality/survival
Primary endpoint: HF-related Hospitalizations
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Changes in Apnea-Hypopnea Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of adverse events (AE) and serious adverse events (SAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Adhesion surface area and intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: MRI/MRS results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Respiratory quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Response rate of CD123 CAR-T treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Morphine and morphine equivalent consumption
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: proportion of placental malaria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Peak Puff Flow Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Electrocardiogram (ECG) assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Micronutrient status (iron, vitamin A, zinc, and iodine)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Posturography
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: End of Life Treatment Preferences
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Fasting Triglyceride Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of Admissions for AECOPD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: In-stent Late Lumen Loss (LLL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Positive and Negative Affect Scale (PANAS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percentage of Participants With Decrease in Average Hemoglobin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Overall accrual
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Readability of Pressure Sensor Measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ultrasonographic measurement of antral area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Liver stiffness measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline Alcohol Use Disorders Identification at 1 Month
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change From Patient Health Questionnaire 9 Item Depression Scale at 1 Month
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Radial access site complications
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Serious Adverse Events (SAEs) Related to ZD1839
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Other Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Other Adverse Events (AEs) Related to ZD1839
Endpoint domain: Adverse events/effects
Primary endpoint: Alveolar bone width
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Paraoxonase activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decreasing weight by 5%
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in muscle protein synthesis response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of hemorrhagic transformation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Rate of good outcomes at 3-month follow-up
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Massachusetts General Hospital Hairpulling Scale (MGHHS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in number of terminal hairs and vellus hair
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in hair shaft thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in terminal and vellus hair density
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-operative air leak rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Sensitivity and Specificity of Red-reflex and Infrared-reflex Testing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hepatic non-heme iron concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Agreement between emergency physician and referee physician echocardiography
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Burden of illness
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change from Baseline Pain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Limiting Toxicity (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: Patient reported rate of alopecia
Endpoint domain: Adverse events/effects
Primary endpoint: Accuracy of repeatability of keratometry
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Magnitude of weight loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: SCORAD (eczema severity score)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CIAS Satisfaction Measure Scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: urine NTX
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of E-cigarette Puffs Used Per Day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Achieving Complete Response (CR) or Partial Response (PR) Based on RECIST 1.1 Criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: global M.D. Anderson Dysphagia Inventory score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Diagnosis of infection of intracardiac device
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in total number of times bike share schemes used
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Breath VCO2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Blood CO2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: incidence of gas bubbles
Endpoint domain: Adverse events/effects
Primary endpoint: performance rate of sentinel lymph node biopsy (SLNB)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: positive rate of sentinel lymph nodes (SLNs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: number of resected sentinel lymph nodes (SLNs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Face Emotion Identification Task (FEIT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Face Emotion Discrimination Task (FEDT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: The Awareness of Social Inference Test (TASIT)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Ambiguous Intentions Hostility Questionnaire (AIHQ)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Incidence of Delayed Neurocognitive Recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Serum prostate specific antigen
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of chemotherapy prescriptions
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Diagnosis accuracy of acute appendicitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Uremic retention solute reduction rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Biocompatibility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Level of accordance between the Biobeat monitor and the arterial line
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Geometric mean titers of neuraminidase inhibiting antibody
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of subjects achieving seroconversion against H7N9 antigen
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: quality of washed red blood cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Absolute reduction of maximal platelet aggregation (Aggmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Neurophysiological changes (response size)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Neurophysiological changes (response timing)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Time to development of incident high-grade serous carcinomas
Endpoint domain: Mortality/survival
Primary endpoint: Six-minute walk performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progression of papillary thyroid microcarcinoma
Endpoint domain: Mortality/survival
Primary endpoint: airway innate immunity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: bronchial infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in Pain Score
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Change From Baseline in Muscle Soreness With Movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: ASCVD Risk Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: overall safety of NeoFuse plus carrier
Endpoint domain: Adverse events/effects
Primary endpoint: Sensitivity of the BD HPV Assay
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Specificity of the BD HPV Assay
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Positive Predictive Value (PPV) of the BD HPV Assay
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Negative Predictive Value (NPV) of the BD HPV Assay
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change From Baseline in Communication
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Amount of SB-568859 in the blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Degree of repigmentation based on modified VASI score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: activated myofibroblasts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Provider attitude toward iSBIRT
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change of Range of motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Symptom Score (TSS) Over Days 2 to 4
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Pain during intracervical block
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tolerability and acceptance of patients
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Reuptake rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Malnutrition Status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: CD11b surface expression on neutrophils
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: C5aR surface expression on neutrophils
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Neurocognitive Function - E/F Function
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Neurocognitive Function - A/P Function
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Neurocognitive Function - L/M Function
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Capillary INR concordance with venous INR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Extubation failure
Endpoint domain: Adverse events/effects
Primary endpoint: postmenstrual spotting
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Histologically Confirmed Recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Prevalence of uncontrolled hypertension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of all cause hospitalization
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Changes in Mother's Body Weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Auditory capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patients With Treatment-Emergent Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Mean Maximum Observed Plasma Concentration (Cmax; Micrograms Per Milliliter [µg/mL]) of GLPG1690
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Area Under the Plasma Concentration-Time Curve (AUC[t]; µg.h/mL) of GLPG1690
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in uncorrected near visual acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Preservation of best corrected visual acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Whose Sample Was Successfully Analysed by Histological Diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent of food purchased that was saturated fat
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion of Sexual Attempts with Erectogenic Effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: International Sexual Function Index (IFIF)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Decrease of pro-inflammatory cytokines in brain extracellular fluid (ECF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Joint position Sense (JPS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Need for Mechanical Ventilation via ET tube at 7 days of life
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Need for Mechanical Ventilation via ET tube at 28 days of life
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of subjects with clinically significant findings in physical examination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of Surgical complication
Endpoint domain: Adverse events/effects
Primary endpoint: Mean change in diurnal systolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Freedom from major adverse limb events (MALE)
Endpoint domain: Adverse events/effects
Primary endpoint: Peri-procedural (30-day) death (POD)
Endpoint domain: Mortality/survival
Primary endpoint: Smoking 7-Day Point Prevalence at 12 Weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration-time curve from zero up to the last analytically quantifiable concentration (AUC(0-t))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration-time curve from zero up to Infinity (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: The maximum plasma concentration of unconjugated Rotigotine (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the gut microbiome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of panic attacks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Visual Analogue Scale for Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absolute change in HbA1c level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Neuropsychological deterioration on the MoCA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: FGF-23 levels during hemodialysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: PTH levels during hemodialysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in severity of movement deviation in the upper limb
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 24hr Calculated blood loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Incidences of Invasive Fungal Diseases
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With One or More Specific Adverse Events (AEs) of Special Interest During the Study
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants Achieving Sustained Virologic Response 24 Weeks After Completion of All Study Therapy (SVR24)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of rising multiple doses of ACH04
Endpoint domain: Adverse events/effects
Primary endpoint: Micronutrient deficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Complete Clearance of AKs at Week 11
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total incidence of grade 3 and 4 adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Total rate of grade 3 and 4 adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum dose level at which 0/3 patients or 1/6 patients experience dose-limiting toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Angle between atrioventricular and ventriculoarterial valves
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Intimate Partner Violence Events
Endpoint domain: Adverse events/effects
Primary endpoint: Drinking Episodes
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Missing Data in the Interactive Questionnaire System (iQS) questionnaire
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Preference for Interactive Questionnaire System (iQS) compared to Audio Computer Assisted Self Interview (ACASI) or Wisepill
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Adherence to Pre-Exposure Prophylaxis (PrEP) Reports by Mode
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: intravesical recurrence-free survival
Endpoint domain: Mortality/survival
Primary endpoint: Maximum Plasma Concentration (Cmax) of Ibrutinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Reach the Maximum Plasma Concentration (Tmax) of Ibrutinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration-Time Curve From 0 to 48 Hours (AUC[0-48]) Post Dose of Ibrutinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Clot Formation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Size of the Late-phase Skin Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in composite facial measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent change from baseline in BMD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent change from baseline in BMC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent change from baseline in BMA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: recurrence of trichomonas
Endpoint domain: Adverse events/effects
Primary endpoint: Functional capacity test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of positive SARS-COV-2 cases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Cross-sectional airspace area of the nasal passages
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes